LEADER 02420nam  2200637Ia 450 
001 9910809134203321
005 20230617011601.0
010   $a0-309-18186-0
010   $a1-282-08332-5
010   $a9786612083327
010   $a0-309-54925-6
035   $a(CKB)1000000000030468
035   $a(SSID)ssj0000195765
035   $a(PQKBManifestationID)11937294
035   $a(PQKBTitleCode)TC0000195765
035   $a(PQKBWorkID)10131781
035   $a(PQKB)11327311
035   $a(MiAaPQ)EBC3377934
035   $a(Au-PeEL)EBL3377934
035   $a(CaPaEBR)ebr10078700
035   $a(CaONFJC)MIL208332
035   $a(OCoLC)923274427
035   $a(EXLCZ)991000000000030468
100   $a20011123d2005      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aMaking better drugs for children with cancer$b[electronic resource] /$fPeter C. Adamson, Susan L. Weiner, Joseph V. Simone, and Hellen Gelband, editors
210   $aWashington, D.C. $cNational Academy of Sciences$d2005
215   $axiv, 42 p
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a0-309-09608-1 
320   $aIncludes bibliographical references.
327   $aChildhood cancers: Background -- Agents in use and in testing for children with cancer -- The existing capacity for developing new agents specifically for childhood cancers -- Putting the pieces together -- Delays in testing approved agents in children -- The need to prioritize agents for testing in children with cancer -- Testing and labeling of drugs for pediatric use.
606   $aAntineoplastic agents
606   $aOncology
615  0$aAntineoplastic agents.
615  0$aOncology.
676   $a618.92/994
701   $aAdamson$b Peter C$01594816
701   $aWeiner$b Susan L$01594817
701   $aSimone$b Joseph V$01594818
701   $aGelband$b Hellen$01594819
712 02$aNational Cancer Policy Board (U.S.).$bCommittee on Shortening the Time Line for New Cancer Treatments.
712 02$aInstitute of Medicine (U.S.)
712 02$aNational Research Council (U.S.)
712 02$aNational Academy of Sciences (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910809134203321
996   $aMaking better drugs for children with cancer$93915519
997   $aUNINA